Page last updated: 2024-11-04

temozolomide and Nausea

temozolomide has been researched along with Nausea in 28 studies

Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.

Research Excerpts

ExcerptRelevanceReference
"In this article, we have compared and analyzed the clinical effects of temozolomide single agent and combined doxorubicin in the treatment of glioma."9.51Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma. ( Chen, L; Liu, Y, 2022)
"CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists."9.34Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020)
"Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration of the adjuvant temozolomide (TMZ) in patients affected by glioblastoma."9.15Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. ( Bria, E; Corona, M; Fabi, A; Lanzetta, G; Minniti, G; Nardoni, C; Restuccia, MR; Rozzi, A, 2011)
"The temozolomide is a promising orally cytotoxic agent used in malignant glioma."8.83The safety of the temozolomide in patients with malignant glioma. ( Dario, A; Tomei, G, 2006)
"Concomitant use of temozolomide (TMZ) and radiotherapy, which is the standard therapy for patients with high-grade glioma, involves a unique regimen with multiple-day, long-term administration."7.83Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T, 2016)
"Temozolomide (TMZ) as a concomitant and adjuvant chemotherapy to radiotherapy following maximal surgical resection is the established standard therapy for patients with newly diagnosed high-grade glioma."7.81Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Nakai, K; Onuma, K; Yamamoto, T, 2015)
"This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy."7.80Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014)
"To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS)."7.75Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. ( Dinter, DJ; Hohenberger, P; Jakob, J; Ströbel, P; Wenz, F, 2009)
"In this article, we have compared and analyzed the clinical effects of temozolomide single agent and combined doxorubicin in the treatment of glioma."5.51Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma. ( Chen, L; Liu, Y, 2022)
"CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists."5.34Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020)
"Cabozantinib inhibits mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) and has demonstrated activity in patients with recurrent glioblastoma, warranting evaluation of the addition of cabozantinib to radiotherapy (RT) and temozolomide (TMZ) for patients with newly diagnosed high-grade glioma."5.22Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. ( Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY, 2016)
"Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration of the adjuvant temozolomide (TMZ) in patients affected by glioblastoma."5.15Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. ( Bria, E; Corona, M; Fabi, A; Lanzetta, G; Minniti, G; Nardoni, C; Restuccia, MR; Rozzi, A, 2011)
"A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer."5.12Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. ( Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006)
"The temozolomide is a promising orally cytotoxic agent used in malignant glioma."4.83The safety of the temozolomide in patients with malignant glioma. ( Dario, A; Tomei, G, 2006)
"Concomitant use of temozolomide (TMZ) and radiotherapy, which is the standard therapy for patients with high-grade glioma, involves a unique regimen with multiple-day, long-term administration."3.83Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T, 2016)
"Temozolomide (TMZ) as a concomitant and adjuvant chemotherapy to radiotherapy following maximal surgical resection is the established standard therapy for patients with newly diagnosed high-grade glioma."3.81Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Nakai, K; Onuma, K; Yamamoto, T, 2015)
"This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy."3.80Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014)
" The observed adverse effects of temozolomide included nausea, vomiting, headache, constipation, mild marrow suppression, and decreased activity; none of them was severe enough to discontinue the treatment."3.75Efficacy of temozolomide for recurrent embryonal brain tumors in children. ( Chang, KP; Hsu, TR; Wang, CH; Wong, TT, 2009)
"To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS)."3.75Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. ( Dinter, DJ; Hohenberger, P; Jakob, J; Ströbel, P; Wenz, F, 2009)
" Additional trials are needed to better define the optimal dosing in such patients."2.77A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. ( Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P, 2012)
"Ratio of log-transformed means (intravenous:oral) of area under the concentration-time curve and maximum concentration of drug after dosing for temozolomide and 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) met exposure equivalence criteria (90% confidence interval = 0."2.75Evaluation of the exposure equivalence of oral versus intravenous temozolomide. ( Abutarif, MA; Cantillon, M; Cutler, D; Diez, BD; Kantesaria, B; Ottaviano, FH; Pallotta, MG; Schwarz, M; Statkevich, P; Xuan, F; Zhu, Y, 2010)
"Primary tumor sites included breast cancer (n=15), lung cancer (n=12) and other (n=5)."2.71Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. ( Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D, 2005)
" Plasma samples were obtained on days 1 and 2 to evaluate the pharmacokinetic parameters of TMZ alone and in combination with CDDP."2.69A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ( Agarwala, SS; Baker, SD; Barrington, R; Britten, CD; Diab, SG; Eckardt, JR; Eckhardt, SG; Fraass, U; Hammond, LA; Johnson, T; Rowinsky, EK; Statkevich, P; Villalona-Calero, M; Von Hoff, DD, 1999)
"Temozolomide (TMZ) has demonstrated clinical antitumor activity."2.45The safety of temozolomide in the treatment of malignancies. ( Hwu, WJ; Patel, SP; Trinh, VA, 2009)
"Nimotuzumab in combination with chemotherapy has moderate activity in patients with malignant gliomas and the toxicities are well tolerable, therefore, worth further investigation."1.37[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. ( Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH, 2011)
"Temozolomide was administered at a dose of 200 mg/m(2) daily for 5 days, in a 4-week cycle."1.34Temozolomide in pediatric low-grade glioma. ( Ashley, DM; Coleman, LT; Downie, PA; Heath, JA; Khaw, SL, 2007)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19901 (3.57)18.7374
1990's1 (3.57)18.2507
2000's10 (35.71)29.6817
2010's12 (42.86)24.3611
2020's4 (14.29)2.80

Authors

AuthorsStudies
Liu, Y1
Chen, L1
Patel, MP2
Woodring, S1
Randazzo, DM1
Friedman, HS1
Desjardins, A2
Healy, P1
Herndon, JE2
McSherry, F1
Lipp, ES1
Miller, E1
Peters, KB1
Affronti, ML2
Morio, K1
Watanabe, J1
Tsujimoto, Y1
Wang, HW1
Xu, ZK1
Song, Y1
Liu, YG1
Calegari, MA1
Inno, A1
Monterisi, S1
Orlandi, A1
Santini, D1
Basso, M1
Cassano, A1
Martini, M1
Cenci, T1
de Pascalis, I1
Camarda, F1
Barbaro, B1
Larocca, LM1
Gori, S1
Tonini, G1
Barone, C1
Yeo, KK1
Puscasiu, E1
Keating, RF1
Rood, BR1
Bae, SH1
Park, MJ1
Lee, MM1
Kim, TM1
Lee, SH1
Cho, SY1
Kim, YH1
Kim, YJ1
Park, CK2
Kim, CY1
Matsuda, M2
Yamamoto, T2
Ishikawa, E2
Nakai, K1
Akutsu, H2
Onuma, K1
Matsumura, A2
Schiff, D1
Cloughesy, T1
Mikkelsen, T1
Glantz, M1
Chamberlain, MC1
Reardon, DA1
Wen, PY1
Jeong, JH1
Hong, YS1
Park, Y1
Kim, J1
Kim, JE1
Kim, KP1
Kim, SY1
Park, JH1
Kim, JH1
Park, IJ1
Lim, SB1
Yu, CS1
Kim, JC1
Kim, TW1
Takano, S1
Dario, A1
Tomei, G1
Wang, CH1
Hsu, TR1
Wong, TT1
Chang, KP1
Zwinkels, H1
Roon, K1
Jeurissen, FJ1
Taphoorn, MJ1
Hop, WC1
Vecht, CJ1
Jakob, J1
Wenz, F1
Dinter, DJ1
Ströbel, P1
Hohenberger, P1
Trinh, VA1
Patel, SP1
Hwu, WJ1
Diez, BD1
Statkevich, P2
Zhu, Y1
Abutarif, MA1
Xuan, F1
Kantesaria, B1
Cutler, D1
Cantillon, M1
Schwarz, M1
Pallotta, MG1
Ottaviano, FH1
Rozzi, A1
Nardoni, C1
Corona, M1
Restuccia, MR1
Fabi, A1
Bria, E1
Minniti, G1
Lanzetta, G1
Yang, QY1
Shen, D1
Sai, K2
Mu, YG2
Jiang, XB1
Zhang, XH2
Chen, ZP2
Portnow, J1
Frankel, P1
Koehler, S1
Twardowski, P1
Shibata, S1
Martel, C1
Morgan, R1
Cristea, M1
Chow, W1
Lim, D1
Chung, V1
Reckamp, K1
Leong, L1
Synold, TW1
Christodoulou, C1
Bafaloukos, D1
Linardou, H1
Aravantinos, G1
Bamias, A1
Carina, M1
Klouvas, G1
Skarlos, D1
Yang, SH1
Kim, MK1
Lee, TK1
Lee, KS1
Jeun, SS1
Kang, JK1
Kim, MC1
Hong, YK1
Rivera, E1
Meyers, C1
Groves, M1
Valero, V1
Francis, D1
Arun, B1
Broglio, K1
Yin, G1
Hortobagyi, GN1
Buchholz, T1
Zhang, JP1
Shi, HL1
Yue, WY1
Khaw, SL1
Coleman, LT1
Downie, PA1
Heath, JA1
Ashley, DM1
Britten, CD1
Rowinsky, EK1
Baker, SD1
Agarwala, SS1
Eckardt, JR1
Barrington, R1
Diab, SG1
Hammond, LA1
Johnson, T1
Villalona-Calero, M1
Fraass, U1
Von Hoff, DD1
Eckhardt, SG1
Wilman, DE1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621]Phase 2135 participants (Actual)Interventional2019-03-25Completed
Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326]Phase 221 participants (Anticipated)Interventional2021-12-01Recruiting
Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347]Phase 118 participants (Anticipated)Interventional2021-01-01Recruiting
Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975]Phase 235 participants (Anticipated)Interventional2022-05-02Recruiting
Preoperative Chemoradiation With Capecitabine Plus Temozolomide in Patients With Locally Advanced Resectable Rectal Cancer: Phase I Study[NCT01781403]Phase 122 participants (Actual)Interventional2013-05-10Completed
A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors[NCT00544284]Phase 125 participants (Actual)Interventional2005-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Maximum Tolerated Dose (MTD)

The MTD is defined as the maximum dose level in the doses of temozolomide tested with capecitabine and radiation in which the incidence proportion of DLT exceeds 30%. (NCT01781403)
Timeframe: 5-6 weeks during study treatment

Interventionmg/m^2 (Number)
Dose Level 10
Dose Level 20
Dose Level 3/Recommended Dose0

Pathological Complete Response

"Pathologic responses and stages were classified according to Dworak's classification and the 7th edition of the American Joint Committee on Cancer staging system, respectively.~The pathologic complete response (pCR) was defined as the total regression of the primary tumor regardless of regional lymph nodal status (ypT0), with residual fibrotic mass or acellular mucin pools only, thus without detectable tumor cells." (NCT01781403)
Timeframe: at the time of surgery (6-8 weeks after study treatment)

Interventionparticipants (Number)
Unmethylated MGMT1
Hypermethylated MGMT6

Recommended Dose (RD)

RD will be defined as one level below the MTD. (NCT01781403)
Timeframe: 5-6 weeks after CRT

Interventionmg/m^2 (Number)
Dose Level 10
Dose Level 20
Dose Level 3/Recommended Dose75

Toxicity(Adeverse Event)

"Toxicity will be monitored and recorded every week during study treatment (5 or 6 weeks) as following according to the NCI-CTCAE version 4.0~An interval history and physical examination with particular attention to drug-induced side effects along with documentation of the patient's weight and performance status will be performed on each visit.~CBC with differential count, blood chemistry including calcium, phosphorus, glucose, BUN, creatinine, total protein, albumin, AST, ALT, alkaline phosphatase, total bilirubin, and electrolyte will be performed before next planned treatment.~All relevant information regarding drug dosage, laboratory examinations, and treatment-related toxicities must be recorded before each treatment is given.~Summaries of the frequency and severity of adverse effects are based on the worst episodes recorded." (NCT01781403)
Timeframe: 5-6 weeks during study treatment

,,
Interventionevents (Number)
Any grade 1 adverse eventAny grade 2 adverse eventAny grade 3 adverse eventAny grade 4 adverse event
Dose Level 16210
Dose Level 28200
Dose Level 3/Recommended Dose601730

Reviews

2 reviews available for temozolomide and Nausea

ArticleYear
The safety of the temozolomide in patients with malignant glioma.
    Current drug safety, 2006, Volume: 1, Issue:2

    Topics: Adult; Antineoplastic Agents, Alkylating; Child; Clinical Trials as Topic; Dacarbazine; Drug Interac

2006
The safety of temozolomide in the treatment of malignancies.
    Expert opinion on drug safety, 2009, Volume: 8, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine;

2009

Trials

12 trials available for temozolomide and Nausea

ArticleYear
Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma.
    Journal of healthcare engineering, 2022, Volume: 2022

    Topics: Doxorubicin; Glioma; Humans; Nausea; Temozolomide; Thrombocytopenia; Treatment Outcome; Vomiting

2022
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:5

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans

2020
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin

2017
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Cancer, 2016, Feb-15, Volume: 122, Issue:4

    Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Asparta

2016
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
    International journal of radiation oncology, biology, physics, 2016, 10-01, Volume: 96, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb

2016
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
    International journal of radiation oncology, biology, physics, 2016, 10-01, Volume: 96, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb

2016
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
    International journal of radiation oncology, biology, physics, 2016, 10-01, Volume: 96, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb

2016
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
    International journal of radiation oncology, biology, physics, 2016, 10-01, Volume: 96, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb

2016
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:4

    Topics: Administration, Oral; Adult; Anemia; Antineoplastic Agents, Alkylating; Area Under Curve; Central Ne

2010
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:5

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modali

2011
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Are

2012
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
    Journal of neuro-oncology, 2005, Volume: 71, Issue:1

    Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brea

2005
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
    Journal of Korean medical science, 2006, Volume: 21, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms;

2006
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
    Cancer, 2006, Sep-15, Volume: 107, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape

2006
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administra

1999

Other Studies

14 other studies available for temozolomide and Nausea

ArticleYear
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:12

    Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting

2020
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:12

    Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting

2020
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
    Cancer gene therapy, 2017, Volume: 24, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; China; Dacarbazine; D

2017
Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide.
    Journal of neurosurgery. Pediatrics, 2013, Volume: 11, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai

2013
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
    Journal of Korean medical science, 2014, Volume: 29, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl

2014
Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
    Neurologia medico-chirurgica, 2015, Volume: 55, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Female;

2015
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
    Neurologia medico-chirurgica, 2016, Nov-15, Volume: 56, Issue:11

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazin

2016
Efficacy of temozolomide for recurrent embryonal brain tumors in children.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2009, Volume: 25, Issue:5

    Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; D

2009
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
    Oncology nursing forum, 2009, Volume: 36, Issue:2

    Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; D

2009
Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma.
    International journal of radiation oncology, biology, physics, 2009, Nov-01, Volume: 75, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarb

2009
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:3

    Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplas

2011
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
    Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi

2006
Temozolomide in pediatric low-grade glioma.
    Pediatric blood & cancer, 2007, Volume: 49, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplati

2007
Prodrugs in cancer chemotherapy.
    Biochemical Society transactions, 1986, Volume: 14, Issue:2

    Topics: Altretamine; Aniline Mustard; Animals; Antineoplastic Agents; Azo Compounds; Biotransformation; Chem

1986